Tzelepi Vasiliki, Gika Helen, Begou Olga, Timotheadou Eleni
Department of Oncology, "Papageorgiou" General Hospital, 56429 Thessaloniki, Greece.
Biomic_Auth, Bioanalysis and Omics Lab, Centre for Interdisciplinary Research of Aristotle University of Thessaloniki, Innovation Area of Thessaloniki, 57001 Thermi, Greece.
Int J Mol Sci. 2023 Sep 11;24(18):13961. doi: 10.3390/ijms241813961.
Lipidomics is a comprehensive study of all lipid components in living cells, serum, plasma, or tissues, with the aim of discovering diagnostic, prognostic, and predictive biomarkers for diseases such as malignant tumors. This systematic review evaluates studies, applying lipidomics to the diagnosis, prognosis, prediction, and differentiation of malignant and benign ovarian tumors. A literature search was performed in PubMed, Science Direct, and SciFinder. Only publications written in English after 2012 were included. Relevant citations were identified from the reference lists of primary included studies and were also included in our list. All studies included referred to the application of lipidomics in serum/plasma samples from human cases of OC, some of which also included tumor tissue samples. In some of the included studies, metabolome analysis was also performed, in which other metabolites were identified in addition to lipids. Qualitative data were assessed, and the risk of bias was determined using the ROBINS-I tool. A total of twenty-nine studies were included, fifteen of which applied non-targeted lipidomics, seven applied targeted lipidomics, and seven were reviews relevant to our objectives. Most studies focused on the potential application of lipidomics in the diagnosis of OC and showed that phospholipids and sphingolipids change most significantly during disease development. In conclusion, this systematic review highlights the potential contribution of lipids as biomarkers in OC management.
脂质组学是对活细胞、血清、血浆或组织中所有脂质成分进行的全面研究,旨在发现恶性肿瘤等疾病的诊断、预后和预测生物标志物。本系统评价评估了将脂质组学应用于恶性和良性卵巢肿瘤的诊断、预后、预测及鉴别诊断的研究。在PubMed、Science Direct和SciFinder数据库中进行了文献检索。仅纳入2012年以后发表的英文文献。从纳入的主要研究的参考文献列表中识别相关引文,并将其纳入我们的列表。所有纳入的研究均涉及脂质组学在卵巢癌患者血清/血浆样本中的应用,其中一些研究还包括肿瘤组织样本。在一些纳入的研究中,还进行了代谢组分析,除脂质外还鉴定了其他代谢物。对定性数据进行了评估,并使用ROBINS-I工具确定偏倚风险。共纳入29项研究,其中15项应用非靶向脂质组学,7项应用靶向脂质组学,7项为与我们目标相关的综述。大多数研究聚焦于脂质组学在卵巢癌诊断中的潜在应用,并表明磷脂和鞘脂在疾病发展过程中变化最为显著。总之,本系统评价强调了脂质作为生物标志物在卵巢癌管理中的潜在作用。